A Study to Learn About COVID-19 Antivirals in People With SARS-CoV-2 Infection From 2023-2026

ClinicalTrials.gov ID: NCT07900139

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07900139. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

CURRENT TREATMENT MANAGEMENT AND OUTCOMES OF INPATIENTS WITH SARS-COV-2

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to learn about the management, treatment, healthcare resource utilization (HCRU), and outcomes of individuals with SARS-CoV-2 infection. This is a retrospective secondary analysis of administrative claims data from 2023-2026, therefore there is no enrollment or participation required. The study will describe and evaluate the real-world management, treatment, HCRU, and outcomes of individuals with SARS-CoV-2 infection.

Study identification

NCT ID: NCT07900139
Recruitment status: Active, not recruiting
Study type: Observational
Phase: Not listed
Lead sponsor: Pfizer; Industry
Enrollment: 1 participant

Conditions and interventions

Conditions

COVID-19 SARS-CoV-2 Infection

Interventions

Patients with COVID-19 Other

Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 20, 2026 (Actual)
Primary completion: Oct 30, 2026 (Estimated)
Completion: Oct 30, 2026 (Estimated)
Last update posted: Oct 28, 2026

2026

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Pfizer New York	New York	New York	10001	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07900139, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 28, 2026 · Synced Nov 14, 2026